Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma 6Urogenital Neoplasms 5Prostatic Neoplasms 5Prostatic Diseases 5Neoplasms by Site 5Neoplasms 5Male Urogenital Diseases 5Genital Neoplasms, Male 5Genital Diseases, Male 4Transitional Cell Cancer of Renal Pelvis and Ureter 1Lung Neoplasms 1Localized Prostate Cancer 1Genital Diseases 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Gemcitabine 113Cisplatin 77Oxaliplatin 46pembrolizumab 35Fluorouracil 33Capecitabine 31durvalumab 27Leucovorin 27lenvatinib 26Magnetic Resonance Spectroscopy 15Irinotecan 14Drug Therapy 13Biopsy 13Nivolumab 12Albumin-Bound Paclitaxel 12tislelizumab 11Specimen Handling 11Radiofrequency Ablation 11130-nm albumin-bound paclitaxel 11pemigatinib 10apatinib 10Taxes 10Radiotherapy 10Floxuridine 10Folfox protocol 9Bevacizumab 9S 1 (combination) 8Platinum 8Photochemotherapy 8Liver Transplantation 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cholangiocarcinoma × padeliporfin × Clear all
NCT00975039 2016-04-18

Study Using WST11 in Patients With Non-Resectable or Inoperable Cholangiocarcinoma

Steba Biotech S.A.

Phase 2 Terminated
8 enrolled
Gastrointestinal

Carcinoma, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡